Table 1.

Pharmacokinetic imaging using MRI of nontargeted and F3-targeted iron oxide–encapsulated nanoparticles in i.c. 9L tumors after i.v. administration

Nontargeted (n = 9)F3 targeted (n = 4)P
Half-life (min)39 ± 3123 ± 12<0.001
CNR 1 hour after3.2 ± 0.65.8 ± 0.60.01
CNR 2 hours after2.4 ± 0.65.2 ± 0.50.008
  • Abbreviation: CNR, contrast-to-noise ratio (relative to baseline).